Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. März 2021 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
23. März 2021 16:22 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
18. März 2021 21:14 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
17. März 2021 16:20 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
15. März 2021 16:15 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function...
04. März 2021 07:35 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant to New Chief Legal Officer

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
04. März 2021 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Appointments to Management Team and Board of Directors

-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...
24. Februar 2021 16:24 ET | Quelle: Solid Biosciences Inc.

Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference

-IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18- -Company to host external key opinion leaders at a...
17. Februar 2021 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
06. Januar 2021 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...

Vorherige Seite